SCHEMBL7336804

SCHEMBL7336804

NN=Cc1ccc2cc(OCC(=O)O)ccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 1/20 0.58
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
CA2 P00918 1/20 0.48
KDM4E B2RXH2 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ALDH1A1 P00352 2/20 0.44
PTPN12 Q05209 1/20 0.43
ALOX15 P16050 2/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MCL1 Q07820 1/20 0.43
LMNA P02545 1/20 0.42
FFAR1 O14842 1/20 0.41
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
PDE2A O00408 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8181856 0.86 ALDH1A1 (0.54) PTPN7KMT2AMEN1ALDH1A1PTPN12
SCHEMBL7344454 0.85 PTGS2 (0.53) PTPN7KMT2AMEN1KDM4EALDH1A1
Hydrochloric Acid SCHEMBL8040373 0.84 ALDH1A1 (0.53) PTPN7KMT2AMEN1ALDH1A1PTPN12
SCHEMBL7346764 0.83 PPARA (0.57) FFAR1PPARGPPARDPPARAPDE2A
SCHEMBL4886687 0.81 PTPN7 (0.65) PTPN7KMT2AMEN1CA2KDM4E
SCHEMBL4076964 0.80 PTPN7 (0.85) PTPN7KMT2AMEN1CA2KDM4E
SCHEMBL2608055 0.80 PTPN7 (0.63) PTPN7KMT2AMEN1CA2KDM4E
Acetic Acid SCHEMBL8382541 0.74 ALDH1A1 (0.45) KMT2AMEN1TDP1ALDH1A1PTPN12
SCHEMBL29367022 0.74 PTPN7 (1.00) PTPN7KMT2AMEN1KDM4ETDP1
SCHEMBL25640 0.74 PTPN7 (1.00) PTPN7KMT2AMEN1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP claimed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PTPN7 3064/4885KMT2A 4585/4885MEN1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.